ReviewCurrent hematologic malignancy reports2026
Germline DDX41 Variants: Current Understanding and Future Directions.
Review in Current hematologic malignancy reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of the reviewTo sumarize, provide an overview, and critically assess the currently available literature pertaining to the detection, management, and prognosis of DDX41 germline predisposition syndrome and related myeloid neoplasms. RECENT
findingsDDX41-germline predisposition syndrome is associated with an increased risk of cytopenias, myelodysplastic syndrome, and acute leukemia. Its association with other hematologic and solid malignancies is evolving. Prognosis needs to be further refined in the context of co-mutations and variant location, especially since conventional prognostic models are not accurate in predicting risk. Management strategies can range from active surveillance to allogeneic hematopoietic stem cell transplantation. DDX41 germline predisposition syndrome represent a distinct biological and clinical entity. Future research should focus on better understanding the patterns of disease progression and timing of therapeutic strategies to optimize clinical outcomes.
Indexed as
Identifiers
42024186What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.